GRNY: Tom Lee Shakes Up Fundstrat's Flagship Fund

Fundstrat Granny Shots US Large Cap ETF (GRNY) was reiterated at "Buy" and has outperformed the S&P 500 by 2.5 percentage points since July 2025. The portfolio has become more balanced, with tech exposure cut below 30% and cyclicals increased, positioning the fund for a broader market rally. The ETF’s weighted-average long-term EPS growth is nearly 14%, supported by a mid-20s P/E multiple that still implies a premium to the S&P 500.

Analysis

The important signal is not that a growth ETF is doing well, but that the leadership mix is rotating toward a more durable late-cycle/widening-advance profile. A portfolio with sub-30% tech and heavier cyclicals should benefit if breadth keeps improving, because earnings revisions will likely shift from a handful of mega-cap AI beneficiaries to industrials, financials, and consumer cyclicals with higher cyclical beta. That makes the fund more sensitive to a steeper curve, easier financial conditions, and a continued soft-landing narrative.

The valuation setup is less attractive than the optics suggest: mid-20s P/E for ~14% long-term EPS growth is only compelling if the market maintains a premium multiple for above-average growth without a rate shock. In practice, the highest-probability failure mode is not underperformance versus the S&P on a one-month basis, but multiple compression over 3-6 months if macro data cools and cyclicals fail to get follow-through. The other risk is factor crowding: if investors crowd into “broadening” exposure too aggressively, the trade becomes consensus and loses its defensive relative-value appeal.

The second-order winners are non-tech cyclicals that get incremental fund flows without requiring heroic margin expansion: capital goods, autos, and select financials. The losers are the crowded mega-cap tech names that were previously doing the heavy lifting; if breadth genuinely improves, their marginal contribution to index returns falls even if absolute earnings remain strong. That creates a subtle but important regime change: the ETF can outperform while the most obvious AI/mega-cap proxy underperforms, which is a cleaner expression of broadening than chasing the index itself.

Contrarian view: the market may be overpricing the durability of breadth. Cyclical participation often looks strongest just before revisions roll over, and a balanced portfolio does not eliminate the need for earnings acceleration in the cyclicals it now owns. If the economy softens or rates back up, the “better balance” argument can turn into a headwind because cyclicals have less valuation support than tech and are more exposed to demand disappointment.

Key Decisions for Investors

• Long XLI vs. short QQQ for 1-3 months: express the broadening-rally thesis without paying for mega-cap tech concentration; target 6-10% relative outperformance if cyclicals continue to lead, with tight stop if semis regain market leadership.
• Buy a modest starter position in GRNY on any 1-2% pullback over the next 2-4 weeks: the cleaner entry is after short-term consolidation, with upside tied to continued breadth expansion; size small because the premium multiple limits margin for error.
• Pair long XLF / short XLK over 2-4 months: if the regime shifts to wider participation and lower concentration, financials should benefit from curve/credit normalization while tech is vulnerable to multiple compression; watch for reversal if rates fall sharply.
• Use GRNY only as a relative-beta trade, not a core long: cap position size at a small overweight versus SPY, since the fund’s higher P/E makes it less attractive if the market enters a risk-off tape or revisions weaken.
• If breadth rolls over, rotate out of cyclicals and back into quality mega-cap tech on a 4-8 week horizon: the key invalidation signal is a renewed concentration in index returns and widening earnings dispersion.